Importer of Controlled Substances Application: Fisher Clinical Services, Inc., 31538 [2021-12350]
Download as PDF
<![CDATA[
31538
Federal Register / Vol. 86, No. 112 / Monday, June 14, 2021 / Notices
other activity for these drug codes is
authorized for this registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2021–12353 Filed 6–11–21; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–849]
Controlled substance
Drug
code
Schedule
Marihuana Extract ....
7350
I
The company plans to import the
above controlled substance as finished
dosage forms for clinical trials. No other
activity for this drug code is authorized
for this registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
Importer of Controlled Substances
Application: Fisher Clinical Services,
Inc.
William T. McDermott,
Assistant Administrator.
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
BILLING CODE P
AGENCY:
Fisher Clinical Services, Inc.
has applied to be registered as an
importer of basic class(es) of controlled
substance(s). Refer to Supplemental
Information listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before July 14, 2021. Such persons
may also file a written request for a
hearing on the application on or before
July 14, 2021.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All request for a hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on May 17, 2021, Fisher
Clinical Services, Inc., 700A–C Nestle
Way, Breinigsville, Pennsylvania
SUMMARY:
lotter on DSK11XQN23PROD with NOTICES1
18031–1522, applied to be registered as
an importer of the following basic
class(es) of controlled substance(s):
VerDate Sep<11>2014
17:26 Jun 11, 2021
Jkt 253001
[FR Doc. 2021–12350 Filed 6–11–21; 8:45 am]
NATIONAL AERONAUTICS AND
SPACE ADMINISTRATION
[Notice: (21–037)]
NASA Astrophysics Advisory
Committee; Meeting
National Aeronautics and
Space Administration.
ACTION: Notice of meeting.
AGENCY:
In accordance with the
Federal Advisory Committee Act, Public
Law 92–463, as amended, the National
Aeronautics and Space Administration
(NASA) announces a meeting of the
Astrophysics Advisory Committee. This
Committee reports to the Director,
Astrophysics Division, Science Mission
Directorate, NASA Headquarters. The
meeting will be held for the purpose of
soliciting, from the scientific
community and other persons, scientific
and technical information relevant to
program planning.
DATES: Tuesday, June 29, 2021, 11:00
a.m.–5:00 p.m., Eastern Time; and
Wednesday, June 30, 2021, 11:00 a.m.–
5:00 p.m., Eastern Time.
FOR FURTHER INFORMATION CONTACT: Ms.
KarShelia Henderson, Science Mission
Directorate, NASA Headquarters,
Washington, DC 20546, (202) 358–2355,
or khenderson@nasa.gov.
SUPPLEMENTARY INFORMATION: The
meeting will be virtual and available to
the public by WebEx and dial-in
teleconference. On Tuesday, June 29,
the event address for attendees is:
SUMMARY:
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
https://nasaenterprise.webex.com/
nasaenterprise/j.php?MTID=
m19281c9d7b875a40a767c1af1f5fd5d4,
the meeting number is 199 024 6323,
and meeting password is 2bkHspPS@65.
On Wednesday, June 30, the event
address for attendees is: https://
nasaenterprise.webex.com/
nasaenterprise/j.php?MTID=
mc4d6d874b2e677b1e6460c8fb1b8df0a,
the meeting number is 199 642 8616,
and meeting password is XZgYwCr2@
65. To join by telephone, the numbers
are: 1–929–251–9612 or 1–415–527–
5035, for each day.
The agenda for the meeting includes
the following topics:
—Astrophysics Division Update
—Updates on Specific Astrophysics
Missions
—Reports from the Program Analysis
Groups
—Report on Science Activation Program
The agenda will be posted on the
Astrophysics Advisory Committee web
page: https://science.nasa.gov/
researchers/nac/science-advisorycommittees/apac.
The public may submit and upvote
comments/questions ahead of the
meeting through the website https://
arc.cnf.io/sessions/qgpt/#!/dashboard
that will be opened for input on June 14,
2021.
It is imperative that the meeting be
held on this date to accommodate the
scheduling priorities of the key
participants.
Patricia Rausch,
Advisory Committee Management Officer,
National Aeronautics and Space
Administration.
[FR Doc. 2021–12446 Filed 6–11–21; 8:45 am]
BILLING CODE 7510–13–P
NATIONAL SCIENCE FOUNDATION
Sunshine Act Meeting
The National Science Board’s ad hoc
Committee on Nominating NSB Class of
2022–2028 (NOMS), hereby gives notice
of the scheduling of a teleconference for
the transaction of National Science
Board business, as follows:
TIME AND DATE: Thursday, June 17, 2021,
from 11:30 a.m.–12:00 p.m. EDT.
PLACE: This meeting will be held by
teleconference through the National
Science Foundation, 2415 Eisenhower
Avenue, Alexandria, VA 22314.
STATUS: Closed.
MATTERS TO BE CONSIDERED: The agenda
of the teleconference is: To review the
master list of NSB Nominees, discuss
review and rating guidance, and receive
reviewing assignments.
E:\FR\FM\14JNN1.SGM
14JNN1
]]>Agencies
[Federal Register Volume 86, Number 112 (Monday, June 14, 2021)]
[Notices]
[Page 31538]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-12350]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-849]
Importer of Controlled Substances Application: Fisher Clinical
Services, Inc.
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Fisher Clinical Services, Inc. has applied to be registered as
an importer of basic class(es) of controlled substance(s). Refer to
Supplemental Information listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may file written comments on or objections to
the issuance of the proposed registration on or before July 14, 2021.
Such persons may also file a written request for a hearing on the
application on or before July 14, 2021.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
request for a hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on May 17, 2021, Fisher Clinical Services, Inc., 700A-C
Nestle Way, Breinigsville, Pennsylvania 18031-1522, applied to be
registered as an importer of the following basic class(es) of
controlled substance(s):
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Marihuana Extract.................... 7350 I
------------------------------------------------------------------------
The company plans to import the above controlled substance as
finished dosage forms for clinical trials. No other activity for this
drug code is authorized for this registration.
Approval of permit applications will occur only when the
registrant's business activity is consistent with what is authorized
under 21 U.S.C. 952(a)(2). Authorization will not extend to the import
of Food and Drug Administration-approved or non-approved finished
dosage forms for commercial sale.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2021-12350 Filed 6-11-21; 8:45 am]
BILLING CODE P
